Symbols

FOLD

Amicus Therapeutics·NASDAQ

--(--)

FOLD fundamentals

FOLD Q3 2025 Earnings

Amicus Therapeutics (FOLD) released its earnings on Nov 4, 2025: revenue was 169.06M (YoY +19.46%), beat estimates; EPS was 0.06 (YoY +400.00%), beat estimates.

Revenue / YoY

169.06M

+19.46%

EPS / YoY

0.06

+400.00%

Report date

Nov 4, 2025

FOLD Earnings Call Summary for Q3,2025

Revenue Growth: Q3 revenue up 19% to $169.1M, driven by 13% Galafold patient growth and 45% Pompe revenue increase.
Profitability Milestone: First quarter of GAAP net income ($17.3M) and positive cash flow generation.
Pompe Momentum: 50-65% full year growth guidance, with 4x patient switch rate in U.S. vs. 2024.
Pipeline Progress: DMX-200 Phase III >90% enrolled, targeting FSGS approval.
Strategic Targets: $1B combined Galafold/Pompe sales by 2028, >50% Pompe market share at peak.

Earnings

EPS

Revenue

Revenue & Expenses

FOLD has released its 2025 Q4 earnings report, with revenue of 185.21M, reflecting a YoY change of 23.72%, and net profit of 1.69M, showing a YoY change of -88.53%. The Sankey diagram below clearly presents FOLD's revenue sources and cost distribution.

Key Indicators

Amicus Therapeutics (FOLD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Amicus Therapeutics (FOLD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Amicus Therapeutics (FOLD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Amicus Therapeutics (FOLD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown